Rusfertide (PTG-300)

About Protagonist Therapeutics

Protagonist Therapeutics is a leader in peptide-based drug discovery, leveraging its proprietary Vectrix™ platform to overcome historical challenges of oral bioavailability and stability. The company has achieved significant milestones, including the FDA approval of icotrokinra for psoriasis and a pending NDA for rusfertide in polycythemia vera. Its strategy combines internal development of wholly-owned assets with strategic partnerships, like the one with Janssen for icotrokinra, to build a diversified, multi-indication portfolio.

Therapeutic Areas

Other Polycythemia Vera Drugs